Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma  Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

Published byRoar Berntsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma  Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,"— Presentation transcript:

1 Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma 
Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff, PhD, Ashley Morrison, BScN, Brian J. Lipworth, MD  Journal of Allergy and Clinical Immunology  Volume 137, Issue 3, Pages e1 (March 2016) DOI: /j.jaci Copyright © 2015 The Authors Terms and Conditions

2 Fig 1 After a 1- to 2-week run-in period, patients received either 12 μg of small-particle HFA-formoterol or 50 μg of large-particle salmeterol dry powder 1 puff twice daily for 1 to 2 weeks each, with a 1- to 2-week washout period in between. Visits 1 and 3 were to assess the first dose, and visits 2 and 4 were to assess the last dose. At each visit, measurements were made at baseline and then over 60 minutes after inhalation. DPI, Dry powder inhaler. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

3 Fig 2 CONSORT diagram to show flow of participants through the study.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

4 Fig 3 Effects on IOS outcomes with either small-particle formoterol or large-particle salmeterol over a 60-minute period after inhaling the first dose shown as the percentage change from baseline. Data are depicted as means and SEMs. For all IOS outcomes, there were significant differences at 5 minutes, which were not sustained over the entire 60-minute period. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

5 Fig 4 Effects on IOS outcomes with either small-particle formoterol or large-particle salmeterol over a 60-minute period after inhaling the last dose shown as percentage change from baseline. Data are depicted as means and SEMs. For all IOS outcomes, there were significant differences between treatments, which were sustained over the 60-minute period. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

Download ppt "Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma  Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma  Patrick Booms, MSca, David.

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma  Patrick Booms, MSca, David.
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol  Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol  Ian D. Pavord, DM, FRCP, Peter K. Jeffery,
Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers  Robert A. Wise,

Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers  Robert A. Wise,
NAEPP Expert Panel Report

NAEPP Expert Panel Report
A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,
The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials 

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials 
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis  George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis  George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Similar presentations

Ads by Google